- Home
- BCAB vs MIRA Comparison
BCAB vs MIRA Comparison
Compare BCAB & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- MIRA
- Stock Information
- Founded
- BCAB 2007
- MIRA 2020
- Country
- BCAB United States
- MIRA United States
- Employees
- BCAB N/A
- MIRA N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- MIRA Biotechnology: Pharmaceutical Preparations
- Sector
- BCAB Health Care
- MIRA Health Care
- Exchange
- BCAB Nasdaq
- MIRA Nasdaq
- Market Cap
- BCAB 22.3M
- MIRA 19.5M
- IPO Year
- BCAB 2020
- MIRA 2023
- Fundamental
- Price
- BCAB $0.38
- MIRA $1.19
- Analyst Decision
- BCAB Buy
- MIRA Strong Buy
- Analyst Count
- BCAB 2
- MIRA 2
- Target Price
- BCAB $1.00
- MIRA $14.00
- AVG Volume (30 Days)
- BCAB 507.7K
- MIRA 1.9M
- Earning Date
- BCAB 08-07-2025
- MIRA 08-12-2025
- Dividend Yield
- BCAB N/A
- MIRA N/A
- EPS Growth
- BCAB N/A
- MIRA N/A
- EPS
- BCAB N/A
- MIRA N/A
- Revenue
- BCAB $11,000,000.00
- MIRA N/A
- Revenue This Year
- BCAB N/A
- MIRA N/A
- Revenue Next Year
- BCAB N/A
- MIRA N/A
- P/E Ratio
- BCAB N/A
- MIRA N/A
- Revenue Growth
- BCAB N/A
- MIRA N/A
- 52 Week Low
- BCAB $0.24
- MIRA $0.51
- 52 Week High
- BCAB $2.53
- MIRA $5.01
- Technical
- Relative Strength Index (RSI)
- BCAB 42.24
- MIRA 46.10
- Support Level
- BCAB $0.36
- MIRA $1.21
- Resistance Level
- BCAB $0.43
- MIRA $1.26
- Average True Range (ATR)
- BCAB 0.04
- MIRA 0.09
- MACD
- BCAB -0.00
- MIRA -0.01
- Stochastic Oscillator
- BCAB 16.00
- MIRA 29.63
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About MIRA MIRA Pharmaceuticals Inc.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.